Bazedoxifene (original) (raw)
From Wikipedia, the free encyclopedia
Chemical compound
Bazedoxifene
 |
|
|---|---|
 |
|
| Clinical data | |
| Trade names | Conbriza, Duavee, Duavive, Viviant |
| Other names | TSE-424; WAY-140424; WAY-TSE-424 |
| AHFS/Drugs.com | International Drug Names |
| License data | EU EMA: by INN |
| Routes of administration | By mouth |
| ATC code | G03XC02 (WHO) |
| Legal status | |
| Legal status | US: WARNING[1] In general: ℞ (Prescription only) |
| Identifiers | |
| IUPAC name 1-[4-[2-(azepan-1-yl)ethoxy]benzyl]-2-(4-hydroxyphenyl)-3-methyl-1_H_-indol-5-ol | |
| CAS Number | 198481-32-2  Y |
| PubChem CID | 154257 |
| IUPHAR/BPS | 7355 |
| DrugBank | DB06401 Y |
| ChemSpider | 135921 Y |
| UNII | Q16TT9C5BK |
| ChEMBL | ChEMBL46740 Y |
| PDB ligand | 29S (PDBe, RCSB PDB) |
| CompTox Dashboard (EPA) | DTXSID70173593  |
| ECHA InfoCard | 100.232.728 |
| Chemical and physical data | |
| Formula | C30H34N2O3 |
| Molar mass | 470.613 g·mol−1 |
| 3D model (JSmol) | Interactive image |
| SMILES Oc1ccc(cc1)c3c(c2cc(O)ccc2n3Cc5ccc(OCCN4CCCCCC4)cc5)C | |
| InChI InChI=1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3 YKey:UCJGJABZCDBEDK-UHFFFAOYSA-N Y |
|
 NY (what is this?) (verify) |
Bazedoxifene, used as bazedoxifene acetate, is a medication for bone problems and possibly (pending more study) for cancer.[2] It is a third-generation selective estrogen receptor modulator (SERM).[3] Since late 2013 it has had U.S. FDA approval for bazedoxifene as part of the combination drug Duavee in the prevention (not treatment) of postmenopausal osteoporosis. It is also being studied for possible treatment of breast cancer and pancreatic cancer.[4]
Bazedoxifene is used in the prevention of postmenopausal osteoporosis.[5]
Osteoporosis represents a major public health concern, especially as the number of postmenopausal women continues to rise. As a result, the need for innovative treatments has become increasingly important. Bazedoxifene (BZA) has emerged as a promising option for postmenopausal osteoporosis due to its demonstrated effectiveness in reducing bone loss and fractures, as well as its strong safety and tolerability profile. For women who cannot or prefer not to use bisphosphonates, owing to gastrointestinal side effects, safety risks, or contraindications, selective estrogen receptor modulators (SERMs) like BZA may serve as a suitable alternative. SERMs may also benefit younger women who are at higher risk of fractures and require long-term treatment.[5]
Furthermore, BZA has been paired with conjugated estrogens (TSEC) for both osteoporosis prevention and the management of menopausal symptoms. Given its positive safety record and efficacy in preventing fractures, BZA is becoming an increasingly important option within the current landscape of osteoporosis therapies.[5]
Bazedoxifene is marketed both alone and in combination with conjugated estrogens.[6]
Bazedoxifene is a selective estrogen receptor modulator (SERM), or a mixed agonist and antagonist of the estrogen receptor (ER) in different tissues.
vte Tissue-specific estrogenic and antiestrogenic activity of SERMs
| Medication | Breast | Bone | Liver | Uterus | Vagina | Brain | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lipids | Coagulation | SHBGTooltip Sex hormone-binding globulin | IGF-1Tooltip Insulin-like growth factor 1 | Hot flashes | Gonadotropins | |||||
| Estradiol | + | + | + | + | + | + | + | + | + | + |
| "Ideal SERM" | – | + | + | ± | ± | ± | – | + | + | ± |
| Bazedoxifene | – | + | + | + | + | ? | – | ± | – | ? |
| Clomifene | – | + | + | ? | + | + | – | ? | – | ± |
| Lasofoxifene | – | + | + | + | ? | ? | ± | ± | – | ? |
| Ospemifene | – | + | + | + | + | + | ± | ± | – | ± |
| Raloxifene | – | + | + | + | + | + | ± | – | – | ± |
| Tamoxifen | – | + | + | + | + | + | + | – | – | ± |
| Toremifene | – | + | + | + | + | + | + | – | – | ± |
| Effect: + = Estrogenic / agonistic. ± = Mixed or neutral. – = Antiestrogenic / antagonistic. Note: SERMs generally increase gonadotropin levels in hypogonadal and eugonadal men as well as premenopausal women (antiestrogenic) but decrease gonadotropin levels in postmenopausal women (estrogenic). Sources: See template. |
The drug is a member of the 2-phenylindole group of SERMs, along with zindoxifene and pipendoxifene.[7]
The drug was approved in the European Union by the European Medicines Agency on April 27, 2009.[8]
Society and culture
[edit]
Bazedoxifene is marketed alone under the brand names Conbriza and Viviant and in combination with conjugated estrogens under the brand names Duavee and Duavive.[6]
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ "DUAVEE® (conjugated estrogens/bazedoxifene) tablets for oral use" (PDF). U.S. Food and Drug Administration. October 2013.
- ^ Biskobing DM (2007). "Update on bazedoxifene: a novel selective estrogen receptor modulator". Clinical Interventions in Aging. 2 (3): 299–303. PMC 2685267. PMID 18044180.
- ^ "Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors". Duke University Medical Center. June 15, 2013.
- ^ a b c Komm BS, Chines AA (February 2012). "Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis". Therapeutic Advances in Musculoskeletal Disease. 4 (1): 21–34. doi:10.1177/1759720X11422602. PMC 3383524. PMID 22870492.
- ^ a b "Bazedoxifene". drugs.com.
- ^ Gribble GW (9 October 2010). Heterocyclic Scaffolds II:: Reactions and Applications of Indoles. Springer Science & Business Media. pp. 14–. ISBN 978-3-642-15732-5.
- ^ "EPARs for authorised medicinal products for human use - Conbriza". European Medicines Agency. 26 May 2009. Archived from the original on 11 June 2009. Retrieved 2009-07-08.